{"database": "openregs", "table": "dockets", "rows": [["FDA-2005-D-0140", "FDA", "Guidance for Industry:  Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV):  Testing, Product Disposition, and Donor Deferral and Reentry;'", "Nonrulemaking", "2021-09-01T01:01:16Z", "0b0000648043fe94"]], "columns": ["id", "agency_id", "title", "docket_type", "last_modified", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2005-D-0140"], "units": {}, "query_ms": 0.5126319592818618, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}